Loading...
Market
What will be the market share of Guardant Health's Shield™ blood test by end of 2024?
2
Resolution / Starting Odds
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Healthcare industry reports and market analysis publications
Story
FDA Approves Guardant Health's Shield™ Blood Test for Colorectal Cancer; Shares Rise 7%
Jul 29, 2024, 03:00 PM
The U.S. Food and Drug Administration (FDA) has approved Guardant Health's Shield™ blood test as a primary screening option for colorectal cancer. This approval marks a significant advancement in cancer detection, particularly for individuals aged 45 and older who are at average risk. The test, which detects cancer in the colon or rectum, is expected to increase screening rates, especially among those who may avoid colonoscopies. Guardant Health's shares rose 7% following the announcement, with a 9.1% increase in premarket trading and a 16% rise in premarket trading on Monday. The approval also paves the way for Medicare reimbursement, potentially making the test more accessible. The FDA's decision was based on data from the ECLIPSE trial. Experts hope that the new test will lead to earlier detection and treatment of colorectal cancer, although it is not a perfect alternative to colonoscopies.
View original story
Similar markets
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 100,000 • 25%
100,000 to 500,000 • 25%
500,000 to 1,000,000 • 25%
More than 1,000,000 • 25%
Guardant Health becomes the market leader • 25%
Guardant Health is among the top 3 • 25%
Guardant Health remains in the top 5 • 25%
Guardant Health does not make it to the top 5 • 25%
0-10% • 25%
11-25% • 25%
26-50% • 25%
51%+ • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
Market share increases • 25%
Market share remains the same • 25%
Market share decreases • 25%
Foresight exits cancer-detection market • 25%
Guardant Reveal • 25%
Guardant360 • 25%
GuardantOMNI • 25%
None • 25%
Yes • 50%
No • 50%